Danegaptide uniquely treats the underlying pathology in patients with diabetic retinopathy, stabilizes intercellular communication, and strengthens both the retina’s inner and outer blood barriers, which decreases vascular leakage and protection of capillary structures and helps remove the subretinal fluid.
Oral danegaptide therapy for these clinically proven conditions has the potential to be a more effective and less burdensome oral therapy for patients with diabetic retinopathy.
The Goal
“To develop a 3D animation to communicate the mechanism of action of the drug and the process of treating the pathology.”
Challenge
Outstanding animation feature: achieving the most precise visual effect through a combination of animation techniques.
Demonstrated capillaries with endotheliocytes and pericytes, depicting the separation of endothelial cells and the flow of erythrocytes. Describing erythrocyte dynamics was a detailed and time-consuming process, with manual animation ensuring visual accuracy. Proportional vessel narrowing relative to pericytes was achieved through diverse animation techniques.
Our Approach
Outstanding animation feature: finding the best individual implementation option.
Such details as cells should look presentable and realistic on the video. Therefore, to achieve the best result, we tried dozens of attempts of different combinations of materials, lighting, and structure. Thanks to this approach and the practice of developing a microscopically stylized material, we managed to show a clear and visually appealing result.
Results
1. High-quality MOA video about small molecule drug that protects from capillary breakdown and vascular leakage by stabilizing cell-cell coupling under high glucose stress and hypoxic conditions.
2. Illustrations to be used on the website and social media.
Project in numbers
8 weeks: Duration from the idea to the final delivery of the video (80 sec).
4 meetings: Communication with client is essential for us. To listen to them and provide with the best result.
2 rounds: Two feedback rounds on the production stage.
“We had a good iterative design process with the team from Nanobot. They were responsive to our input on biological processes and found good solutions for the design. I am very pleased with the result.” — Ulrik Mouritzen, Founder and CEO at Breye Therapeutics ApS.
